

03CO



OIPE


RAW SEQUENCE LISTING DATE: 02/04/2002 PATENT APPLICATION: US/10/036,729 TIME: 12:02:38

Input Set: N:\Crf3\RULE60\10036729.raw
Output Set: N:\CRF3\02042002\J036729.raw

SEQUENCE LISTING

```
3 (1) GENERAL INFORMATION:
             (i) APPLICANT: Middeldorp, Jaap Michiel.
     7
            (ii) TITLE OF INVENTION: Peptides and nucleic acid sequences
     8
                                      related to the Epstein-Barr virus.
     10
           (iii) NUMBER OF SEQUENCES: 22
     12
            (iv) CORRESPONDENCE ADDRESS:
                  (A) ADDRESSEE: Akzo-Nobel Patent Department
     13
                  (B) STREET: 1300 Piccard Drive, Suite 206
     14
     15
                  (C) CITY: Rockville
                  (D) STATE: Maryland
     16
                                                           ENTERED
                  (E) COUNTRY: USA
     17
     18
                  (F) ZIP: 20850
             (V) COMPUTER READABLE FORM:
     20
     21
                  (A) MEDIUM TYPE: Floppy disk
                  (B) COMPUTER: IBM PC compatible
     22
                  (C) OPERATING SYSTEM: PC-DOS/MS-DOS
     23
                  (D) SOFTWARE: Patentin Release #1.0, Version #1.25
     24
            (vi) CURRENT APPLICATION DATA:
     26
                  (A) APPLICATION NUMBER: US/10/036,729
C--> 27
                  (B) FILING DATE: 21-Dec-2001
C--> 28
           (vii) PRIOR APPLICATION DATA:
     30
                  (A) APPLICATION NUMBER: 08/415,838
     31
     32
                  (B) FILING DATE:
          (viii) ATTORNEY/AGENT INFORMATION:
     34
     35
                  (A) NAME: Gormley, Mary E.
     36
                  (B) REGISTRATION NUMBER: 34,409
       (2) INFORMATION FOR SEQ ID NO: 1:
     38
     40
             (i) SEQUENCE CHARACTERISTICS:
                  (A) LENGTH: 538 base pairs
     41
     42
                  (B) TYPE: nucleic acid
                  (C) STRANDEDNESS: double
     43
                  (D) TOPOLOGY: unknown
     44
     46
            (ii) MOLECULE TYPE: DNA (genomic)
     48
            (vi) ORIGINAL SOURCE:
     49
                  (A) ORGANISM: Epstein-Barr virus
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
                                                                                 60
     54 CATGATGGCA CGCCGGCTGC CCAAGCCCAC CCTCCAGGGG AGGCTGGAGG CGGATTTTCC
                                                                                120
     56 AGACAGTCCC CTGCTTCCTA AATTTCAAGA GCTGAACCAG AATAATCTCC CCAATGATGT
     58 TTTTCGGGAG GCTCAAAGAA GTTACCTGGT ATTTCTGACA TCCCAGTTCT GCTACGAAGA
                                                                                180
     60 GTACGTGCAG AGGACTTTTG GGGTGCCTCG GCGCCAACGC GCCATAGACA AGAGGCAGAG
                                                                                240
     62 AGCCAGTGTG GCTGGGGCTG GTGCTCATGC ACACCTTGGC GGGTCATCCG CCACCCCCGT
                                                                                300
     64 CCAGCAGGCT CAGGCCGCCG CATCCGCTGG GACCGGGGCC TTGGCATCAT CAGCGCCGTC
                                                                                360
```





66 CACGGCCGTA GCCCAGTCCG CGACCCCCTC TGTTTCTTCA TCTATTAGCA GCCTCCGGGC	420										
••••••	480										
	538										
70 TGGCGGGGGA CAACCCCACG ACACCGCCCC ACGCGGGGCA CGTAAGAAAC AGTAGCCC 538 72 (2) INFORMATION FOR SEQ ID NO: 2:											
74 (i) SEQUENCE CHARACTERISTICS:	• •										
75 (A) LENGTH: 176 amino acids											
76 (B) TYPE: amino acid											
77 (C) STRANDEDNESS: single	•										
78 (D) TOPOLOGY: linear											
80 (ii) MOLECULE TYPE: peptide											
82 (vi) ORIGINAL SOURCE:											
83 (A) ORGANISM: Epstein-Barr virus											
86 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:											
88 Met Ala Arg Arg Leu Pro Lys Pro Thr Leu Gln Gly Arg Leu Glu Ala											
89 1 5 10 15											
91 Asp Phe Pro Asp Ser Pro Leu Leu Pro Lys Phe Gln Glu Leu Asn Gln											
92 20 25 30											
94 Asn Asn Leu Pro Asn Asp Val Phe Arg Glu Ala Gln Arg Ser Tyr Leu											
95 35 40 45											
97 Val Phe Leu Thr Ser Gln Phe Cys Tyr Glu Glu Tyr Val Gln Arg Thr											
98 50 55 60											
100 Phe Gly Val Pro Arg Arg Gln Arg Ala Ile Asp Lys Arg Gln Arg Ala											
101 65 70 75 80											
103 Ser Val Ala Gly Ala Gly Ala His Ala His Leu Gly Gly Ser Ser Ala											
104 85 90 95											
106 Thr Pro Val Gln Gln Ala Gln Ala Ala Ser Ala Gly Thr Gly Ala											
107 100 105 110											
109 Leu Ala Ser Ser Ala Pro Ser Thr Ala Val Ala Gln Ser Ala Thr Pro											
110 115 120 125 112 Ser Val Ser Ser Ser Ile Ser Ser Leu Arg Ala Ala Thr Ser Gly Ala											
112 Ser var ser ser ser rie ser ser het arg ara ara rin ser Gry ara 113 130 135 140											
115 Thr Ala Ala Ala Ser Ala Ala Ala Ala Val Asp Thr Gly Ser Gly Gly											
116 145 150 155 160											
118 Gly Gly Gln Pro His Asp Thr Ala Pro Arg Gly Ala Arg Lys Lys Gln											
119 165 170 175 175 175 175 175 175 177 177 177 177											
122 (2) INFORMATION FOR SEQ ID NO: 3:											
124 (i) SEQUENCE CHARACTERISTICS:											
125 (A) LENGTH: 1038 base pairs											
126 (B) TYPE: nucleic acid											
127 (C) STRANDEDNESS: double											
128 (D) TOPOLOGY: unknown											
130 (ii) MOLECULE TYPE: DNA (genomic)											
132 (vi) ORIGINAL SOURCE:											
133 (A) ORGANISM: Epstein-Barr virus											
136 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:											
138 ATGCTATCAG GTAACGCAGG AGAAGGAGCA ACAGCCTGCG GAGGTTCGGC CGCCGCGGGC	60										
140 CAGGACCTCA TCAGCGTCCC CCGCAACACC TTTATGACAC TGCTTCAGAC CAACCTGGAC	120										
142 AACAAACCGC CGAGGCAGAC CCCGCTACCC TACGCGGCCC CGCTGCCCCC CTTTTCCCAC	180										
144 CAGGCAATAG CCACCGCGCC TTCCTACGGT CCTGGGGCCG GAGCGGTCGC CCCGGCCGGC	240										





RAW SEQUENCE LISTING DATE: 02/04/2002 PATENT APPLICATION: US/10/036,729 TIME: 12:02:38

																GTGCC	300
																TACTTT	360
	-															CACTTG	420
																SAGGAG	480
																SACATA	540
																CGGGAG	600
158	ACG	CTGT	CCT A	ACGG(CCAC	C C	GGAG	CGG	A TAC	CTGC	CCCC	AGC	AGGG	CCC (CTGCT	TACACC	660
160	CAC	CGGC	GGC (CTTA(CGGAT	T T	CAGC	CTCAT	CA	AAGC	racg	AAG	rgcco	CAG A	ATACO	STCCCT	720
162	CATO	CCGC	CCC (CACC	ACCA	AC T	rctc <i>i</i>	ACCAG	GC2	AGCTO	CAGG	CGC	AGCC:	rcc z	ACCC	CCGGGC	780
164	ACAC	CAGG	CCC (CCGA	AGCCC	CA C	rgtgi	rGGCC	GAG	STCC	ACGA	TCC	CTGAC	GGC (GGGAC	CAGCC	840
166	GGG	ACTO	CTG (GACC	CCGGC	SA GO	GACAC	CAAC	CC	rcag(CAGC	CCA	CCAC	CGA (GGGC	CACCAC	900
168	CGCC	GAA	AGA A	AACT	GTG	CA GO	GCCT	CTGC	TC	CGGAC	GTGG	CTC	AGTC	raa (GGAG	CCCACC	960
170	ACCO	CCA	AGG (CCAAC	STCTO	GT G	rcag(CCAC	CTO	CAAG	гсса	TCT	rttg	CGA (GGAAT	TGCTG	1020
170 ACCCCCAAGG CCAAGTCTGT GTCAGCCCAC CTCAAGTCCA TCTTTTGCGA GGAATTGCTG 172 AATAAACGCG TGGCTTGA											1038						
172 AATAAACGCG IGGCIIGA 174 (2) INFORMATION FOR SEQ ID NO: 4:																	
174 (2) INFORMATION FOR SEQ 1D NO. 4. 176 (i) SEQUENCE CHARACTERISTICS:																	
177		(- ,					45 an			is							
178			•	-			no ac		401								
179			•	•			ESS:		ıle								
180			•	•			line	-	,								
182		/ii	•	•			pept										
184			•		AL SO			JIUC									
		(V I .					Epst	oin-	- Darı	r wii	rue						
185		/ari 1					requ PTI(
188	36-4												Crra	C117	C111	Cor	
		Leu	ser	GTA		Ala	GTA	GIU	СТА		TILL	Ата	Cys	GTĀ	Gly 15	261	
191				~ 1	5		-	-1 -	a	10	D		>	m b		M-+	
	Ala	Ala	Ата	_	GIn	Asp	Leu	11e		vaı	Pro	Arg	ASI		Phe	мес	
194	1	_	_	20	m1		. .		25	T	n	D	3	30	m1	Desc	
	Thr	Leu		GIn	Thr	Asn	Leu	_	Asn	rys	Pro	Pro		GIN	Thr	Pro	
197	_	_	35			_	_	40	_	-1	_		45		-1.		
	Leu		Tyr	Ala	Ala	Pro			Pro	Pne	Ser		GIn	Ala	Ile	Ala	
200		50				_	55 ·		_			60	_	_			
		Ala	Pro	Ser	${ t Tyr}$	_	Pro	Gly	Ala	Gly		Val	Ala	Pro	Ala		
203						70					75			_	_	80	
	Gly	Tyr	Phe	Thr		Pro	Gly	Gly	Tyr		Ala	Gly	Pro	Ala	Gly	Gly	
206					85					90					95		
208	Asp	Pro	Gly	Ala	Phe	Leu	Ala	Met	Asp	Ala	His	Thr	Tyr	His	Pro	His	
209				100					105					110			
211	Pro	His	Pro	Pro	Pro	Ala	Tyr	Phe	Gly	Leu	Pro	Gly	Leu	Phe	Gly	Pro	
212			115					120					125				
214	Pro	Pro	Pro	Val	Pro	Pro	Tyr	Tyr	Gly	Ser	His	Leu	Arg	Ala	Asp	Tyr	
215		130					135					140					
217	Val	Pro	Ala	Pro	Ser	Arg	Ser	Asn	Lys	Arg	Lys	Arg	Asp	Pro	Glu	Glu	
	145					150			-	_	155	_	-			160	
		Glu	Glu	Glv	Glv		Leu	Phe	Pro	Glv		Asp	Ala	Thr	Leu	Tyr	
221	F			1	165	1				170		- 1			175	-	
	Arσ	Lvs	Asp	IJe		G] v	Leu	Ser	Lvs		Va l	Asn	Glu	Leu	Gln	His	
224	5	-15		180		1			185					190		•	
	ጥb r	T.eu	Gln		T.eu	Ara	Ara	Glu		Leu	Ser	Tur	Glv		Thr	Glv	
220	TIIT	படம	OTII	птα	Leu	n = 9	27.9	Jru	T 111	J.Cu	UU_1	- <u>y</u> -	- $ I$			J-1	





DATE: 02/04/2002 RAW SEQUENCE LISTING TIME: 12:02:38 PATENT APPLICATION: US/10/036,729

227	195				200					205			
229 Val	Gly Tyr	Cys Pro	Gln	Gln	Gly	Pro	Cys	Tyr	Thr	His	Ser	Gly	Pro
230	210			215					220				
232 Tyr	Gly Phe	Gln Pro	His	Gln	Ser	Tyr	Glu	Val	${\tt Pro}$	Arg	Tyr	Val	Pro
233 225			230					235					240
235 His	Pro Pro	Pro Pro	Pro	Thr	Ser	His	Gln	Ala	Ala	Gln	Ala	Gln	Pro
236		245					250					255	
238 Pro	Pro Pro	Gly Thr	Gln	Ala	${\tt Pro}$	Glu	Ala	His	Cys	Val	Ala	Glu	Ser
239		260				265					270		
241 Thr	Ile Pro	Glu Ala	Gly	Ala	Ala	Gly	Asn	Ser	Gly	${\tt Pro}$	Arg	Glu	Asp
242	275				280					285			
244 Thr	Asn Pro	Gln Gln	Pro	Thr	Thr	Glu	Gly	His	His	Arg	Gly	Lys	Lys
245	290			295					300				
247 Leu	Val Gln	Ala Ser	Ala	Ser	Gly	Val	Ala	Gln	Ser	Lys	Glu	${\tt Pro}$	Thr
248 305			310					315					320
250 Thr	Pro Lys	Ala Lys	Ser	Val	Ser	Ala	His	Leu	Lys	Ser	Ile	Phe	Cys
251		325					330					335	
253 Glu	Glu Leu	Leu Asn	Lys	Arg	Val	Ala							
254		340				345							
256 (2)	INFORMAT	TION FOR	SEQ	ID N	10: 5	5:							
258	(i) SEQ	QUENCE CI	HARAC	TER	STI	CS:							
259	· ·												
260	(B	3) TYPE:	amin	o ac	cid								
261													
262	•												
264													
266	•, •												
267	(A	A) ORGAN	ISM:	Epst	ein:	Barı	c vi	rus					
270	(xi) SEQ	QUENCE D	ESCRI	PTIC	ON: 5	SEQ 1	D NO): 5	:				
272 Ala	Val Asp	Thr Gly	Ser	Gly	Gly	Gly	Gly	Gln	Pro	His	Asp	Thr	Ala
273		5					10					15	
275 Pro	Arg Gly	Ala Arg	Lys	Lys	Gln								
276		20											
279 (2)	INFORMAT	TION FOR	SEQ	ID N	10: 6	5:							
281	(i) SEQ	QUENCE C	HARAC	TER	STIC	CS:							
282	(A	A) LENGT	H: 30	ami	ino a	acids	3						
283	(B	B) TYPE:	amin	o ac	cid								
284	(0	C) STRANI	DEDNE	SS:	sing	jle							
285	(D) TOPOLO	OGY:	line	ear								
287	(ii) MOL	LECULE T	YPE:	pept	ide								
289	(vi) ORI	GINAL S	OURCE	:									
290	(A	A) ORGAN	ISM:	Epst	ein-	Barı	r vi	cus					
293	(xi) SEC	QUENCE D	ESCRI	PTIC	ON: S	SEQ I	D NO	0: 6	:				
295 Ser	Thr Ala	Val Ala	Gln	Ser	Ala	Thr	${\tt Pro}$	Ser	Val	Ser	Ser	Ser	Ile
296		5					10					15	
298 Ser	Ser Leu	Arg Ala	Ala	Thr	Ser	Gly	Ala	Thr	Ala	Ala	Ala		
299		20				25					30		
301 (2)	INFORMAT	TION FOR	SEQ	ID N	10: 7	7:							
303	(i) SEQ	QUENCE CI	HARAC	TER	STIC	CS:							



RAW SEQUENCE LISTING DATE: 02/04/2002 PATENT APPLICATION: US/10/036,729 TIME: 12:02:38

```
(A) LENGTH: 15 amino acids
304
305
              (B) TYPE: amino acid
306
              (C) STRANDEDNESS: single
307
              (D) TOPOLOGY: linear
309
        (ii) MOLECULE TYPE: peptide
        (vi) ORIGINAL SOURCE:
311
              (A) ORGANISM: Epstein-Barr virus
312
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
315
317 Gly Val Pro Arg Arg Gln Arg Ala Ile Asp Lys Arg Gln Arg Ala
                                                              15
                                         10
318
320 (2) INFORMATION FOR SEQ ID NO: 8:
        (i) SEQUENCE CHARACTERISTICS:
322
323
              (A) LENGTH: 15 amino acids
324
              (B) TYPE: amino acid
325
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
326
328
        (ii) MOLECULE TYPE: peptide
330
        (vi) ORIGINAL SOURCE:
331
              (A) ORGANISM: Epstein-Barr virus
334
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
336 Gly Gln Pro His Asp Thr Ala Pro Arg Gly Ala Arg Lys Lys Gln
339 (2) INFORMATION FOR SEQ ID NO: 9:
341
         (i) SEQUENCE CHARACTERISTICS:
342
              (A) LENGTH: 12 amino acids
              (B) TYPE: amino acid
343
              (C) STRANDEDNESS: single
344
              (D) TOPOLOGY: linear
345
        (ii) MOLECULE TYPE: peptide
347
        (vi) ORIGINAL SOURCE:
349
350
              (A) ORGANISM: Epstein-Barr virus
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
353
355 Thr Ala Val Ala Gln Ser Ala Thr Pro Ser Val Ser
                                         10
                    5
358 (2) INFORMATION FOR SEQ ID NO: 10:
360
         (i) SEQUENCE CHARACTERISTICS:
361
              (A) LENGTH: 12 amino acids
362
              (B) TYPE: amino acid
              (C) STRANDEDNESS: single
363
              (D) TOPOLOGY: linear
364
366
        (ii) MOLECULE TYPE: peptide
368
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Epstein-Barr virus
369
372
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
374 Pro Ser Val Ser Ser Ser Ile Ser Ser Leu Arg Ala
377 (2) INFORMATION FOR SEQ ID NO: 11:
379
         (i) SEQUENCE CHARACTERISTICS:
380
              (A) LENGTH: 12 amino acids
```



VERIFICATION SUMMARY

PATENT APPLICATION: US/10/036,729

DATE: 02/04/2002 TIME: 12:02:39

Input Set : N:\Crf3\RULE60\10036729.raw
Output Set: N:\CRF3\02042002\J036729.raw

L:27 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]

L:28 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]